|
gptkbp:instance_of
|
gptkb:CAR_T-cell_therapy
|
|
gptkbp:administration_setting
|
gptkb:hospital
|
|
gptkbp:advocacy
|
required
|
|
gptkbp:approves
|
gptkb:2017
gptkb:FDA
|
|
gptkbp:associated_with
|
gptkb:immunotherapy
|
|
gptkbp:clinical_trial
|
Phase 2
specific conditions
ongoing research
positive outcomes
ZUMA-1
multiple centers
|
|
gptkbp:clinical_use
|
variable
oncology
|
|
gptkbp:developed_by
|
patient's T-cells
|
|
gptkbp:duration
|
variable
|
|
gptkbp:effective_date
|
October 2017
|
|
gptkbp:eligibility
|
specific criteria
|
|
gptkbp:events
|
long-term
monitoring for side effects
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:funding
|
various sources
|
|
gptkbp:healthcare
|
gptkb:Oncology
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Yescarta
|
|
gptkbp:indication
|
relapsed or refractory large B-cell lymphoma
|
|
gptkbp:ingredients
|
gptkb:tisagenlecleucel
|
|
gptkbp:is_monitored_by
|
critical
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:marketed_as
|
gptkb:Yescarta
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
genetically modifies T-cells
|
|
gptkbp:patient_education
|
important
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:post_treatment_monitoring
|
essential
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_guidance_on
|
available
outpatient
|
|
gptkbp:regulatory_compliance
|
approved
|
|
gptkbp:related_to
|
CAR T-cell therapies
|
|
gptkbp:research_focus
|
hematologic malignancies
|
|
gptkbp:route_of_administration
|
intravenous
single infusion
|
|
gptkbp:serves
|
gptkb:large_B-cell_lymphoma
|
|
gptkbp:side_effect
|
cytokine release syndrome
infection risk
neurological toxicities
|
|
gptkbp:targets
|
gptkb:CD19
|
|
gptkbp:treatment
|
personalized medicine
monitored
remission
variable success rates
improved response rates
|
|
gptkbp:treatment_limitations
|
not suitable for all patients
|
|
gptkbp:type
|
gptkb:gene_therapy
|
|
gptkbp:type_of_insurance
|
may vary
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
|
|
gptkbp:bfsLayer
|
4
|